Novavax Applies For Emergency Use Approval Of Its Covid Vaccine In India

Novavax CEO Stanley Erck called the submissions an "important step toward access to millions of doses of a safe and effective vaccine for countries with an urgent need to control the pandemic."

US-based vaccine maker Novavax has filed regulatory submissions for emergency use authorization in India. The submission was made to the Drugs Controller General of India (DCGI) through its partner, Serum Institute of India (SII), which also manufactures the Covishield vaccine which is being administered in the country. Apart from India, Novavax has also asked regulators in Indonesia and the Philippines to allow emergency use of its COVID-19 vaccine. Later this month, the US vaccine maker plans to seek the World Health Organization review to be part of the COVAX global vaccine programme. Novavax CEO Stanley Erck called the submissions an "important step toward access to millions of doses of a safe and effective vaccine for countries with an urgent need to control the pandemic." In India, the US pharma giant has partnered with Serum Institute of India to manufacture, develop and sell the vaccine. Novavax and SII have cumulative commitments to provide more than 1.1 billion doses to the COVAX Facility.